Quantifying age-associated differences in the durability of Shingrix-induced immunity using mathematical modelling
Understanding the durability of vaccine-induced immunity is critical for evaluating long-term protection and vaccine scheduling, particularly in aging populations where immunosenescence may alter immune response dynamics. In this study, we used a novel mathematical modelling pipeline to quantify age-related differences in the contraction and persistence phases of gE-specific CD4+ T cell and anti-gE antibody responses following Shingrix vaccination. Specifically, we developed a semi-mechanistic model to expand virtual populations that captured inter-individual variability in peak concentrations and waning dynamics. To compare immune responses across age groups, we introduced a time varying, age-related immune advantage metric that measures the probability of a randomly selected younger individual exhibiting a stronger immune response than one from an older group. By evaluating this metric across multiple simulated virtual populations, our results demonstrate clear and sustained age-related differences in both gE-specific CD4+ T cells and anti-gE antibody responses, with younger age groups consistently exhibiting higher responses. Given these age-related differences, we used our model to explore alternative vaccine schedules in older age groups. These exploratory simulations suggest that booster doses administered between 6 and 12 months following the second dose may mitigate age-related differences in antibody dynamics. This work highlights the use of mechanistic mathematical modelling to disentangle age-associated differences in vaccine outcomes and lead to designing of plausible improvement in age-specific vaccine schedules.
Authors
- Morgan Craig (ORCID: https://orcid.org/0000-0003-4852-4770)
- David A. G. Skibinski (ORCID: https://orcid.org/0000-0001-8528-2278)
- Guy De La Rosa (ORCID: https://orcid.org/0000-0002-0416-1843)
- Soren M. Gantt (ORCID: https://orcid.org/0000-0001-5743-3606)
- Lisa Shelton
- Terry Easlick (ORCID: https://orcid.org/0000-0002-2735-0284)
- Haijing Qin
Institutions
- Centre Hospitalier Universitaire Sainte-Justine (CA)
- Institut de Recherche Vaccinale (FR)
- CHU Sainte-Justine Research Center (CA)
- Université de Montréal (CA)
Publication Details
- Journal
- medRxiv
- Published
- 2026-11-12
- DOI
- https://doi.org/10.64898/2026.11.10.26367539
- Primary Topic
- Herpesvirus Infections and Treatments
- Type
- preprint